Orbimed Advisors LLC Position in Clovis Oncology INC (CLVS) Cut by $12.87 Million

Clovis Oncology, Inc. (NASDAQ:CLVS) LogoInvestors sentiment decreased to 1.2 in 2019 Q2. Its down 0.55, from 1.75 in 2019Q1. It dropped, as 32 investors sold CLVS shares while 33 reduced holdings. 22 funds opened positions while 56 raised stakes. 48.57 million shares or 0.75% less from 48.93 million shares in 2019Q1 were reported. Wells Fargo Mn accumulated 0% or 51,108 shares. Trexquant Invest Ltd Partnership accumulated 0.01% or 10,567 shares. Cubist Systematic Strategies Lc reported 144,265 shares. San Francisco Sentry Investment Grp Inc (Ca) holds 600 shares or 0% of its portfolio. Nomura invested in 0% or 9,000 shares. Voloridge Inv Ltd Liability Co holds 0.02% or 45,175 shares. Susquehanna Intl Grp Llp invested in 491,332 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 2,754 shares. The Ontario – Canada-based Bancorporation Of Montreal Can has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Tekla Capital Mngmt Ltd Company has 0.02% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). Citadel Advsrs Lc holds 0.01% or 1.34 million shares in its portfolio. Balyasny Asset Mngmt Ltd Liability stated it has 0.04% in Clovis Oncology, Inc. (NASDAQ:CLVS). Dekabank Deutsche Girozentrale reported 45,589 shares. Ameritas Inv Ptnrs Inc stated it has 3,967 shares. Barclays Public Limited Company holds 0% or 206,936 shares.

Since August 16, 2019, it had 1 buying transaction, and 0 insider sales for $279,576 activity.

Orbimed Advisors Llc decreased its stake in Clovis Oncology Inc (CLVS) by 32.45% based on its latest 2019Q2 regulatory filing with the SEC. Orbimed Advisors Llc sold 919,066 shares as the company’s stock declined 40.43% . The hedge fund held 1.91 million shares of the health care company at the end of 2019Q2, valued at $28.45M, down from 2.83M at the end of the previous reported quarter. Orbimed Advisors Llc who had been investing in Clovis Oncology Inc for a number of months, seems to be less bullish one the $280.00M market cap company. The stock decreased 5.25% or $0.3 during the last trading session, reaching $5.41. About 2.99 million shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 75.79% since September 13, 2018 and is downtrending. It has underperformed by 75.79% the S&P500.

Orbimed Advisors Llc, which manages about $6.70 billion and $6.46B US Long portfolio, upped its stake in Amarin Corp Plc (NASDAQ:AMRN) by 367,600 shares to 717,600 shares, valued at $13.91 million in 2019Q2, according to the filing. It also increased its holding in Bristol Myers Squibb Co (NYSE:BMY) by 150,200 shares in the quarter, for a total of 1.35 million shares, and has risen its stake in Adverum Biotechnologies Inc.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on October, 29. They expect $-1.82 EPS, down 6.43 % or $0.11 from last year’s $-1.71 per share. After $-2.27 actual EPS reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts -19.82 % EPS growth.

More notable recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Streetinsider.com which released: “Clovis Oncology (CLVS) to Offer $225 Million of Convertible Senior Notes – StreetInsider.com” on August 07, 2019, also Seekingalpha.com with their article: “Clovis chief opens wallet to buy stock – Seeking Alpha” published on August 19, 2019, Seekingalpha.com published: “Clovis down 5% on positive data for PARP competitor Lynparza – Seeking Alpha” on August 07, 2019. More interesting news about Clovis Oncology, Inc. (NASDAQ:CLVS) were released by: Nasdaq.com and their article: “Here’s Why Clovis Oncology Stock Dropped as Much as 13% Today – Nasdaq” published on April 15, 2019 as well as Seekingalpha.com‘s news article titled: “Clovis up 31% premarket on Tesaro deal – Seeking Alpha” with publication date: December 03, 2018.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.